

Form PTO-1449 (modified)		Atty. Docket No.: UVMO:023US	Serial No.: 10/520,408
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Thomas P. Quinn Natalia G. Karasseva	
		Filing Date: May 17, 2005	Group: 1643
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
/ALH/	A1	5,578,482	11/26/96	Lippman <i>et al.</i>	435	384	07/26/93
	A2	5,874,528	02/23/99	Lupu <i>et al.</i>	530	317	10/27/94
	A3	5,985,553	11/16/99	King <i>et al.</i>	435	6	06/07/95
	A4	6,414,130	07/02/02	Doherty <i>et al.</i>	536	23.5	07/31/00
	A5	6,417,168	07/09/02	Greene <i>et al.</i>	514	44	07/08/98
	A6	6,426,400	07/30/02	Zalutsky	530	330	04/26/00
↓	A7	6,884,418	04/26/05	Shawver <i>et al.</i>	424	155.1	01/18/91

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

25741146.1

EXAMINER: /Anne Holleran/ (06/23/2007) DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UVMO:023US	Serial No. 10/520,408
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thomas P. Quinn Natalia G. Karasseva	
		Filing Date: January 3, 2005	Group: Unknown 1643
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/ALH/	C11	McInnes and Sykes, "Growth Factor Receptors: Structure, Mechanism, and Drug Discovery", <i>Biopolymers</i> , 43(5):339-366, 1997.
	C12	Oldenburg <i>et al.</i> , "Peptide ligands for a sugar-binding protein isolated from a random peptide library", <i>Proc. Natl. Acad. Sci., USA</i> , 89:5393-5397, 1992.
	C13	Piccart, Perry (Ed.), American Soc. Clinical Oncology, Alexandria, VA, Integration of New Therapies Into Management of Metastatic Breast Cancer: A Focus on Chemotherapy, Treatment Selection Through Use of Molecular Markers, and Newly Developed Biologic Therapies in Late Clinical Development. "In: <i>American Society of Clinical Oncology Educational Book</i> ", 1999.
	C14	Weiner <i>et al.</i> , "Phase I Trial of 2B1, a Bispecific Monoclonal Antibody Targeting c-erbB-2 and FcyRIII " <i>Cancer Res.</i> , 55(20):4586-4593, 1995.
	C15	Wiechen <i>et al.</i> , "C-erbB-2 anti-sense phosphorothioate oligodeoxynucleotides inhibit growth and serum-induced cell spreading of p185 ^{c-erbB-2} overexpressing ovarian carcinoma cells" <i>Int. J. Cancer</i> 63(4):604-608, 1995.
↓	C16	Wrighton <i>et al.</i> , "Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin" <i>Science</i> 273, 458-463, 1996.

25514576.1

EXAMINER: /Anne Holleran/ (06/23/2007)	DATE CONSIDERED:
--	------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.


INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



Atty. Docket No.

JVMO:023US

Serial No.

10/520,408

Applicant

Thomas P. Quinn

Natalia G. Karasheva

Filing Date:

January 3, 2005

Group:

Unknown

1643

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
ALH	C1	Alimandi <i>et al.</i> "Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors", <i>EMBO J</i> , 16(18):5608-5617, 1997.
	C2	Ballinger <i>et al.</i> , "Selection of Heregulin Variants Having Higher Affinity for the ErbB3 Receptor by Monovalent Phage Display", <i>J Biol. Chem.</i> , 273(19): 11675-11684, 1998.
	C3	Baselga <i>et al.</i> , "Recombinant Humanized Anti-HER2 Antibody (Herceptin TM) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/ <i>neu</i> Overexpressing Human Breast Cancer Xenografts", <i>Cancer Res.</i> , 58:2825-2831, 1998.
	C4	Devlin <i>et al.</i> , "Random Peptide Libraries: A Source of Specific Protein Binding Molecules", <i>Science</i> , 249:404-406, 1990.
	C5	Disis <i>et al.</i> , "Generation of Immunity to the HER-2/ <i>neu</i> Oncogenic Protein in Patients with Breast and Ovarian Cancer Using a Peptide-based Vaccine", <i>Clin. Cancer Res.</i> , 5(6):1289-1297, 1999.
	C6	Giebel <i>et al.</i> , "Screening of Cyclic Peptide Phage Libraries Identifies Ligands That Bind Streptavidin with High Affinities" <i>Biochemistry</i> , 34:15430-15435, 1995.
	C9	Jones <i>et al.</i> , "Binding Interaction of the Heregulin β egf Domain with ErbB3 and ErbB4 Receptors Assessed by Alanine Scanning Mutagenesis", <i>J. Biol. Chem.</i> , 273(9):11667-11674, 1998.
✓	C10	Kay <i>et al.</i> , "An M13 phage library displaying random 38-amino-acid peptides as a source of novel sequences with affinity to selected targets", <i>Gene</i> 128:59-65, 1993.

25514576.1

EXAMINER: /Anne Holleran/ (06/23/2007)

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.
UVMO:023USSerial No.
10/520,408

List of Patents and Publications for Applicant's

Applicant

Thomas P. Quinn

Natalia G. Karasseva

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
January 3, 2005

Group:

Unknown

1643

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/ALH/	C7	Harris <i>et al.</i> , "Gene therapy for cancer using tumour-specific prod", <i>Gene Therapy</i> , 1:170-5, (1994).
/ALH/	C8	Jinno <i>et al.</i> , "Effectiveness of an Adriamycin Immunoconjugate that Recognizes the C-erb B-2 Product on Breast Cancer Cell Lines", <i>Surgery today</i> , 26:501-7, (1996).

25514576.1

EXAMINER: /Anne Holleran/ (06/23/2007)

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

